期刊文献+

nm23/NDPK和CD44s在前列腺癌的表达及意义

Immunohistochemical study of nm 23/NDPK and CD44s expression in human prostate cancer
下载PDF
导出
摘要 目的 :探讨nm2 3/NDPK和CD4 4s在前列腺癌中的表达及意义。方法 :用免疫组织化学染色方法以及微波抗原修复法分别检测 4 0例前列腺癌标本中nm 2 3/NDPK和CD4 4s的表达情况。结果 :在 4 0例前列腺癌标本中nm 2 3/NDPK的阳性表达为 5 7.5 0 % (2 3/4 0 ) ,CD4 4s的阳性表达为 4 0 .0 0 % (16 /4 0 )。nm 2 3/NDPK的表达随病理分化程度降低而下调 ,转移组 (36 .84 % )明显低于非转移组 (76 .19% ) ,P <0 .0 5。CD4 4s的表达随前列腺癌病理分化程度降低而下调。转移组 (5 .5 6 % )明显低于非转移组 (6 8.12 % ) ,P <0 .0 1。随前列腺癌whitmore分期的增高 ,nm 2 3/NDPK与CD4 4s表达明显下调。结论 :nm 2 3基因与CD4 4s在前列腺癌侵袭转移过程中发挥重要作用 ,检测nm 2 3与CD4 4s的表达对评价前列腺癌的生物学行为 。 Purpose:To study the role of nm 23/NDPK and CD 44 s in carcinogenesis and metastasis of human prostate cancer.Methods:The expression of nm 23/NDPK and CD 44 s was analyzed immunohistochemistry in 40 patients with prostate cancer.Results:Among 40 case 23( 57.5 %) have strongly positive expression of nm23/NDPK in the cytoplasm,16(40%)showed strongly positive expression of CD44s protein on the membranous. The strongly positive expression of nm23/NDPK showed down regulation with pathological stage and differentiation. Compared with the group of non metastasis( 76.19 %), the positive expression of nm23/NDPK in the group of metastasis( 36.84 %) decreased significantly.CD44s protein had like results.Conclusions:Measuring the expression of nm23 and CD44s may be a great aid in evaluating the biological behavior of human prostate cancer and predicting tumor recurrence and progression.
出处 《临床泌尿外科杂志》 2003年第9期548-550,共3页 Journal of Clinical Urology
关键词 前列腺肿瘤 免疫组织化学 NM23基因 NM23/NDPK CD44S 基因表达 Prostate neoplasms Immunohistochemistry nm23 gene CD44
  • 相关文献

参考文献2

  • 1[1]Kallakury B V, Yang F, Figge J, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Cancer,1996,78:1461-1461.
  • 2[2]Magabhushan M, Wytske M, Marion J, et al. Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Am J Clin Pathol,1996,106:647-647.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部